	US 12,233,046 B2
	Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
Blake Mandell, Brooklyn, NY (US); Martin Stogniew, Lakewood Ranch, FL (US); and Jennifer Louise Schmidt, Garden City, NY (US)
Assigned to TRANSCEND THERAPEUTICS, INC., New York, NY (US)
Filed by Transcend Therapeutics, Inc., New York, NY (US)
Filed on May 9, 2024, as Appl. No. 18/659,413.
Application 18/659,413 is a continuation of application No. 18/215,547, filed on Jun. 28, 2023, granted, now 12,059,402.
Application 18/215,547 is a continuation of application No. 17/887,962, filed on Aug. 15, 2022, granted, now 11,707,446, issued on Jul. 25, 2023.
Application 17/887,962 is a continuation of application No. PCT/US2022/074369, filed on Aug. 1, 2022.
Claims priority of provisional application 63/230,237, filed on Aug. 6, 2021.
Claims priority of provisional application 63/240,113, filed on Sep. 2, 2021.
Claims priority of provisional application 63/255,706, filed on Oct. 14, 2021.
Claims priority of provisional application 63/325,757, filed on Mar. 31, 2022.
Claims priority of provisional application 63/328,343, filed on Apr. 7, 2022.
Prior Publication US 2024/0293357 A1, Sep. 5, 2024
Int. Cl. A61K 31/36 (2006.01); A61K 45/06 (2006.01); A61P 25/22 (2006.01); A61P 25/24 (2006.01)

CPC A61K 31/36 (2013.01) [A61K 45/06 (2013.01); A61P 25/22 (2018.01); A61P 25/24 (2018.01)]

29 Claims

1. A method of treating a Depressive Disorder and/or ameliorating a symptom thereof in a subject in need thereof, comprising: administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising MBDB (N-methyl-1-(1,3-benzodioxol-5-yl)-2-aminobutane) or a pharmaceutically acceptable salt thereof, and/or an enantiomer thereof, and/or a polymorph thereof.